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Abstract A subgroup of patients with metastatic 
carcinomas of unknown origin may benefit from 
combination chemotherapy. The relevance of immuno- 
histochemistry in detecting such patients was investi- 
gated. Immunohistochemical studies with a panel of 
antibodies were performed on the tissue specimens 
of 41 patients having a light-microscopic diagnosis of 
poorly differentiated adenocarcinoma or undifferen- 
tiated carcinoma of unknown origin, who had been 
treated with cisplatin-containing chemotherapy. The 
study aimed to answer the following questions: (a) Can 
the tissue type of the tumor be verified? (b) Can a pri- 
mary organ site be identified? (c) Can a prognostic 
immunohistochemical profile be recognized? The orig- 
inal diagnosis had to be changed in 2 of the 41 patients, 
who turned out to have a malignant lymphoma nd 
neuroblastoma, respectively. The primary site was diag- 
nosed in a patient with prostate cancer, whereas in 
one case the diagnosis could be narrowed down to 
a neuroendocrine tumor. No certain immunohis- 
tochemical profile with prognostic significance could 
be identified. It was concluded that immunohistochem- 
istry should be routinely used in cases of undifferen- 
tiated carcinoma of unknown primary origin to verify 
the histological diagnosis and to select he appropriate 
therapy. 
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Introduction 
Malignant umors are traditionally classified according 
to site of origin, tissue type, and histological subtype. 
Consequently, a variety of tumors can be recognized, 
each with its specific biological behavior and prognosis. 
The choice of treatment is mainly related to the site of 
origin of the tumor and to the tissue type, especially 
where patients with metastatic malignancies are con- 
cerned. 
In 0.5 %-15 % of the cases presenting with metastatic 
tumors the primary tumor site is not found, despite 
extensive diagnostic procedures (Holmes and Fouts 
1970; Didolkar et al. 1977; Nystrom et al. 1979; Woods 
et al. 1980; Neumann and Nystrom 1982; Le Chevalier 
et al. 1988). The prognosis in these cases is generally 
poor due to poor response to chemotherapy. 
Previous studies, both by us and by others, have 
shown that a subgroup of metastatic carcinomas are 
chemosensitive, and may therefore have a better prog- 
nosis in terms of response rates and survival (Hains- 
worth et al. 1988; van der Gaast 1990). Some of the 
characteristics of this subgroup are rapid tumor 
growth, young age, midline distribution of the tumor 
and poor histological differentiation. At the Vanderbilt 
University Medical Center an update on 220 patients 
with undifferentiated carcinomas or poorly differenti- 
ated adenocarcinomas of unknown primary site, treated 
with cisplatin-containing re imens, howed an objective 
response in 63% of the patients, with an actuarial 10- 
year survival of 16% (Hainsworth et al. 1992a). 
182 
The clinical utility of immunoperoxidase staining in 
patients with a light-microscopic diagnosis of undif- 
ferentiated carcinomas or poorly differentiated aden- 
ocarcinomas ofunknown primary site was reported by 
Hainsworth and co-workers in 1991 (Hainsworth et al. 
1991). In 14 patients (16%) out  of a group of 87, 
immunohistochemistry led to a different diagnosis, 
including lymphoma nd melanoma. In 24 patients the 
results were inconclusive, but a more specific diagnosis 
could be made in 7 out of 18 patients by means of 
electron microscopy performed on the tissue speci- 
mens. 
This report describes an investigation of the rel- 
evance of immunohistochemical analyses performed on 
the histological specimens in a similar subgroup of 
patients. The aims of this study were: 
1. To verify the light-microscopic classification of the 
tissue type of the tumor. 
2. To assess whether the application of a panel of 
antibodies contributes to the identification ofa primary 
organ site. 
3. To assess the prognostic significance of various im- 
munohistochemical profiles. 
Materials and methods 
Immunohistochemical studies were performed on the tissue speci- 
mens of 41 patients with a carcinoma of unknown primary origin 
treated with chemotherapy. 
Tumors were considered to be of unknown primary site if, after 
a thorough istory and physical examination, chest X-ray, routine 
blood morphology and chemistry tests, mammography in women, 
palpation and visualization of the female pelvic organs and an 
assessment of tumor markers uch as prostate-specific antigen, fl- 
human chorionic gonadotropin (HCG) and c<-fetoprotein (AFP), no 
primary site could be identified. 
The treatment regimen consisted of intravenous administration f 
20 mg/m 2cisplatin on days 1-5, 120 mg/m 2etoposide on days 1,3, 
and 5, and 30 mg bleomycin on days, 2,9, and 16. Four cycles were 
given at 3-week intervals. 
Only patients with a light-microscopic diagnosis of poorly 
differentiated adenocarcinoma or undifferentiated carcinoma, 
meeting at least one of the following criteria, were entered (Greco 
et al. 1986): 
1. Age under 50 years (particularly men) 
2. Tumor predominantly located in a midline distribution (medias- 
tinum or retroperitoneum), ultiple pulmonary nodules or lym- 
phadenopathy 
3. Clinical evidence of rapid tumor growth. 
A tumor was classified as a poorly differentiated adenocarcinoma 
when features like rudimentary gland formation and/or intracellular 
vacuoles with evidence of mucin production were present. If none of 
these characteristics was found, the tumor was classified as undif- 
ferentiated carcinoma. 
Tumor response was evaluated by standard WHO criteria 
(WHO 1979). Duration of survival was calculated from the start- 
ing date of chemotherapy, Patient characteristics are listed in 
Table 1. 
Table 1 Patient charactristics 
No. patients 41 
Sex 
Female 23 (56%) 
Male 18 (44%) 
Median age (years) 50 
Range 21-61 
Median performance (WHO) 1 
Range 0-2 
Histology 
Poorly differentiated adenocarcinoma 23 (56%) 
Undifferentiated carcinoma 18 (44%) 
Response 
Complete response 5 (12%) 
Partial response 17 (41%) 
Stable disease 12 (29%) 
Progressive disease 7 (17%) 
Immunohistochemistry 
Immunohistochemical st ining was performed on paraffin sections, 
using the indirect immunoperoxidase method. Staining results were 
recorded as either positive or negative for each case. A positive 
control section was included in each staining series. Phosphate- 
buffered saline, non-immune ascites fluid or normal rabbit 
immunoglobulin were used as negative controls (Henzen-Logmans 
et al. 1987). 
In order to verify the tumor tissue type, the following antibodies 
were selected in appropriate dilutions: monoclonal ntibody (mAb) 
CAM 5.2 (cytokeratin 8, 18) (Becton Dickinson, USA); mAB 2662 
(broad-spectrum keratin) (DakoPatts, Denmark); polyclonal pVi 
(vimentin) (Eurodiagnostics Organon Teknika, The Netherlands); 
mAb NKI/C3 against melanoma-associated antigen glycoprotein 
90-34 (kindly provided by Dr. Claus Vennegoor, NCI, Amsterdam, 
The Netherlands); DAKO-LCA (CD45) (DakoPatts, Denmark ). 
In order to identify the primary tumor site, the following tumor- 
selective or tumor-associated antibodies were used: mAb CEA (car- 
cinoembryonic antigen) (Eurodiagnostics Organon Teknika, The 
Netherlands); mAb OV632 against ovarian-associated antigen, 
(Monosan 9003; Sambio, Uden, The Netherlands); and mAb A577 
(calcitonin), A251 (thyroglobulin), A008 (AFP), A231 (fiHCG), A627 
(PZF), L1838 (PSA) all purchased from DakoPatts, Denmark; and 
mAb OC125 (HistoCIS, France). 
Statistical methods 
The following factors were analyzed for prognostic significance: 
histology and immunohistochemical staining for cytokeratins, 
vimentin, NKI/C3, CEA, OV632, calcitonin, thyrogtobin, AFP, 
fiHCG, PZF and PSA. Survival curves were calculated according to 
the Kaplan-Meier method (Kaplan and Meier 1958) and differences 
between the survival curves were tested using the log-rank test 
(Mantel 1966). A P- value below 0.05 was considered to be signifi- 
cant. 
Results 
Patients with a revised tissue type or 
definitive diagnosis 
Of the 41 patients, 39 had tumors reactive to the 
anti-cytokeratin antibodies, which suggests epithelial 
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differentiation of the tumor. The tumor of 1 of the 
2 remaining patients reacted with the anti-leukocyte 
common antibody (LCA). This patient was referred to 
our department with a diagnosis of undifferentiated 
carcinoma but, after additional immunohistochemical 
studies, proved to have a malignant large-cell non- 
Hodgkin lymphoma. He had a complete response after 
four cycles of chemotherapy and, more than 5 years 
after the initial diagnosis, the patient is now disease- 
free. The other cytokeratin-negative patient had a tu- 
mor that only reacted with anti-vimentin. After addi- 
tional electron microscopy a tentative diagnosis of 
neuroblastoma was made. This latter patient achieved 
a partial response to chemotherapy for 12 months, and 
survived for 18 months. Apart from the one above- 
mentioned patient no other tumors reacted with 
anti-LCA. 
One tumor (in a 45-year-old patient) reacted with 
L1838, which is directed against prostate-specific anti- 
gen (PSA). This patient presented with a poorly differ- 
entiated adenocarcinoma with bone metastases and 
rapidly growing lymph node metastases in the neck. 
Rectal examination was initially reported to be nega- 
tive. On reception of the immunology results a histo- 
logical biopsy of the prostate was performed, revealing 
a carcinoma of the prostate, which also turned out to 
be PSA-positive. 
months after start of treatment without evidence of 
disease progression. 
Immunohistochemical p tterns requiring 
further investigations 
In 17 patients the tumors stained with NKI/C3. 
NKI/C3 reacts with an antigen, glycoprotein 90-34, 
expressed in the cytoplasm of melanoma cells. How- 
ever, like other melanoma-associated antigens, 
NKI/C3 reactivity may also be present in a variety of 
other tumors (Vennegoor et al. 1985). NKI/C3 often 
reacts with neuroendocrine tumors and also with mu- 
cin-producing tumors of the breast and lung. Especially 
degenerating cells are often NKI/C3-positive. In 3 pa- 
tients the tumors stained with cytokeratins as well as 
with vimentin and NKI/C3. As melanomas normally 
express vimentin but may also express cytokeratin 
(Zarbo et al. 1990), additional studies were performed 
in these 3 patients. Electron microscopy performed on 
the material of i patient showed no premelanosomes or 
melanosomes. Additional staining for S-100 protein 
and melanin was negative in the 2 other cases. In none 
of the 17 patients could melanoma be established as 
the primary diagnosis. 
Patients with tumors positive for one or 
more tumor-associated antigens 
In i patient he tumor stained with anti-calcitonin. This 
patient presented with rapidly growing liver metastases 
of unknown origin. There was no clinical evidence of 
a (medullary) carcinoma of the thyroid. The initial 
histological findings were compatible with a poorly 
differentiated adenocarcinoma. Additional staining 
revealed that this tumor also expressed neuron-specific 
enolase and chromogranine A, a reaction pattern char- 
acteristic for a neuroendocrine tumor. The patient did 
not respond to chemotherapy and died 3 months after 
start of treatment. 
In the female patients, immunohistochemical studies 
with OV-632 and OC-125 monoclonal antibodies, 
directed against non-mucinous ovarian carcinomas, 
were performed. None of the tumors expressed OV-632 
and only one tumor reacted with OC-125. Post-mor- 
tem examination in this patient did not reveal any 
primary tumor, ovarian or otherwise. 
The tumors of 2 patients were/~HCG-positive. One 
of these was the previously mentioned patient with 
prostate cancer. The other patient was a woman who 
presented with axillary and supraclavicular lymph 
node metastases of a poorly differentiated adenocar- 
cinoma without any evidence of a germ-cell tumor, 
apart from the immunology result. This patient par- 
tially responded to chemotherapy and was still alive 28 
Prognostic relevance of certain 
immunohistochemical profiles 
A total of 16 patients had tumors that stained with 
anti-CEA. Of these 16 cases, 14 had a histological 
diagnosis of poorly differentiated a enocarcinoma. The 
clinical diagnosis could not be narrowed own in any 
of these cases. No difference in survival (P = 0.64) was 
observed between the 16 patients with CEA-positive 
tumors and the 25 CEA-negative ones. Likewise, no 
Table 2 Prognostic significance of histology and certain immuno- 
histochemical profiles 
Variable Response Median Significance: 
rate (%) survival P 
(months) 
Histology 
Adenocarcinoma 39 6 0.23 
(n = 23) 
Undifferentiated 72 9 
carcinoma (n = 18) 
Vimentin expression 
Positive (n = 7) 57 6 0.49 
Negative (n = 34) 51 8 
NKI/C3-expression 
Positive (n = 17) 47 5 0.08 
Negative (n = 24) 58 8 
CEA-expression 
Positive (n = 16) 50 7 0.64 
Negative (n = 25) 56 6 
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Fig. 1 Survival curve for all patients (n = 41) 
survival difference (P -- 0.51) was observed between the 
7 vimentin-positive cases and the 34 vimentin-negative 
ones, or between the 17 patients with NKI/C3-positive 
tumors and the 24 NKI/C3-negative patients 
(P = 0.08). The influence of the various parameters on 
response and survival is shown in Table 2. No discre- 
pancies could be found in the immunoprofiles of the 
patients with a survival of less than 12 months, as 
opposed to those with a survival of more than 12 
months after the start of treatment. The survival curve 
for all patients is shown in Fig. 1. 
Discussion 
Despite the development of sophisticated examination 
methods, such as computed tomography and magnetic 
resonance imaging, the detection of the primary site of 
a metastatic solid malignancy remains a problem. It is 
well known that patients with carcinoma of unknown 
primary site carry a poor prognosis, not only because 
the majority of them present with far advanced isease 
with extensive bone or liver metastases, but also 
because most tumors are refractory to drug therapy 
(Ultmann 1991). However, a subset of patients does 
have a better prognosis after treatment with cisplatin- 
containing chemotherapy. These patients are charac- 
terized by features uch as rapid tumor growth, young 
age, midline distribution of the tumor, and an undif- 
ferentiated histology (Hainsworth et al. 1988, 1992b; 
van der Gaast et al. 1990). 
We have investigated the value of immunohis- 
tochemical analysis of metastatic tumor tissue in this 
subgroup of patients. As a result, in 2 patients (5%), the 
tissue diagnosis was changed to a malignant lymphoma 
and neuroblastoma respectively. In 1 patient with 
a poorly differentiated calcitonin-positive adeno- 
Carcinoma, the diagnosis could be refined to a neuro- 
endocrine tumor. The primary organ site could be 
diagnosed in 1 patient with prostate cancer. 
In the previously mentioned study of Hainsworth 
et al. the tissue diagnosis had to be changed in 17 of the 
87 patients (20%), while in another 4 patients a diag- 
nosis of the primary organ site or a diagnosis refine- 
ment could be made (Hainsworth et al. 1991). The low 
percentage of changed iagnoses in our study may be 
due to the fact that the majority of our patients were 
referred from other centers, and that a light-microscop- 
ic review of the pathology of the tissue specimens had 
taken place before the patients entered this study. 
In the group of patients we studied, no histological 
or immunohistochemical characteristics ould be iden- 
tified to discriminate between good or poor prognosis. 
Although the response rate to chemotherapy was sig- 
nificantly (P = 0.03) higher in patients with undifferen- 
tiated carcinomas (72%) than in patients with poorly 
differentiated adenocarcinomas (39%), the survival 
curves of these two groups are similar. Greco et al. also 
found a higher response rate in patients with undif- 
ferentiated carcinomas compared to patients with 
poorly differentiated adenocarcinomas of unknown 
origin treated with cisplatin-containing chemotherapy. 
However, in a multivariate analysis, histology was not 
shown to have an independent predictive value for 
survival (Greco and Hainsworth 1990; Hainsworth 
et al. 1992b). 
We found more adenocarcinomas than undifferen- 
tiated carcinomas to be CEA-positive, as was to be 
expected (Goslin et al. 1981), but CEA expression had 
no prognostic significance for either response or sur- 
vival. Some reports suggest hat vimentin expression 
may be a poor prognostic indicator (Raymond and 
Leong 1989; Domagala et al. 1990), but the patients' 
survival pattern in our study showed no correlation 
with vimentin expression. None of the tested antibod- 
ies, or combination of antibodies, appeared to yield 
a subgroup of patients with prognostic benefit. 
The results of this study confirm that a pathology 
review, including light microscopy and immunohis- 
tochemistry, will elucidate the precise tissue and primary 
organ site diagnosis in about 5% of cases, and support 
the contention that immunohistochemistry with a re- 
stricted panel of antibodies, uch as applied here, should 
be routinely used in cases of undifferentiated carcinoma 
of unknown primary origin to verify the histological 
diagnosis and to select he appropriate therapy. 
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